Yedidya Saiman, MD, PhD, Assistant Professor of Medicine at the Lewis Katz School of Medicine at Temple University, offered insight to the Philadelphia Inquirer on Rezdiffra, or resmetirom, which has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of scarring and inflammation caused by abnormal accumulations of fat in the liver. The condition is known as metabolic dysfunction-associated steatohepatitis (MASH), or fatty liver disease. Dr. Saiman was not involved in the study of Rezdiffra.
Temple Faculty Physicians is experiencing technical issues with phone lines. If you are experiencing an emergency, please visit your nearest emergency room. If you would like to schedule an appointment with your provider or have general questions or requests, please contact us by using myTempleHealth.
myTempleHealth
800-TEMPLE-MED
Schedule Appointment
SEARCH TEMPLE HEALTH